The epidemiology of acute promyelocytic leukaemia, Best Practice & Research Clinical Haematology, vol.16, issue.3, pp.357-367, 2003. ,
DOI : 10.1016/S1521-6926(03)00065-3
High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia, Blood, vol.88, p.377, 1996. ,
About the increased frequency of acute promyelocytic leukemia among Latinos: the experience from a center in Spain, Blood, vol.88, pp.2357-2358, 1996. ,
Promyelocytic leukemia in Mexican Mestizos, Blood, vol.89, pp.348-349, 1997. ,
Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia, Leukemia, vol.11, issue.10, pp.1661-1664, 1997. ,
DOI : 10.1038/sj.leu.2400783
High relative proportion of acute promyelocytic leukemia in children: experience of a multicenter study in Cuba, Leukemia Research, vol.24, issue.8, pp.739-740, 2000. ,
DOI : 10.1016/S0145-2126(00)00012-6
The migrations and adaptations of the first Americans: Clovis and pre-clovis views from South American The First Americans: The Pleistocene Colonization of the New World, pp.159-223 ,
Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARalpha fusion gene, British Journal of Haematology, vol.84, issue.4, pp.563-570, 2003. ,
DOI : 10.1016/0092-8674(91)90113-D
More on Geographic Hematology: The Breakpoint Cluster Regions of the PML/RAR?? Fusion Gene in Mexican Mestizo Patients with Promyelocytic Leukemia are Different from Those in Caucasians, Leukemia & Lymphoma, vol.52, issue.1, pp.1365-1368, 2004. ,
DOI : 10.1159/000205529
High incidence of acute promyelocytic leukemia in the Caucasian population: The Costa Rica experience, American Journal of Hematology, vol.7, issue.1, pp.96-97, 2004. ,
DOI : 10.1093/oxfordjournals.annonc.a058400
Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: Population-based data, BMC Cancer, vol.37, issue.1, p.33, 2005. ,
DOI : 10.1002/mpo.1217
Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain, Leukemia Research, vol.30, issue.8, pp.943-948, 2006. ,
DOI : 10.1016/j.leukres.2005.12.025
Influence of increased body mass index on drug toxicity in patients with acute promyelocytic leukemia, Leukemia, vol.12, issue.9, pp.1503-1506, 1998. ,
DOI : 10.1038/sj.leu.2401126
Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience, Blood, vol.100, issue.6, pp.1972-1978, 2002. ,
DOI : 10.1182/blood-2001-12-0312
Therapy-Related Acute Promyelocytic Leukemia, Journal of Clinical Oncology, vol.21, issue.11, pp.2123-2160, 2003. ,
DOI : 10.1200/JCO.2003.09.072
DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia, New England Journal of Medicine, vol.352, issue.15, pp.1529-1567, 2005. ,
DOI : 10.1056/NEJMoa042715
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis, Blood, vol.112, issue.8, pp.3383-90, 2008. ,
DOI : 10.1182/blood-2007-10-115600
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia, Blood, vol.115, issue.2, pp.326-356, 2010. ,
DOI : 10.1182/blood-2009-07-235051
Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis, Haematologica, vol.96, issue.4, pp.621-626, 2011. ,
DOI : 10.3324/haematol.2010.036657
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA, Mediterranean Journal of Hematology and Infectious Diseases, vol.3, issue.1, p.2011045, 2011. ,
DOI : 10.4084/mjhid.2011.045
CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint, Leukemia, vol.9, pp.1461-1466, 1995. ,
CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform, American Journal of Hematology, vol.94, issue.1, pp.34-41, 2001. ,
DOI : 10.1046/j.1365-2141.1996.d01-1838.x
Expression of CD2 in Acute Promyelocytic Leukemia Correlates With Short Form of PML-RAR?? Transcripts and Poorer Prognosis, American Journal of Clinical Pathology, vol.121, issue.3, pp.402-407, 2004. ,
DOI : 10.1309/XC8P9M8NKQDT38LB
The biological characteristics of CD34+CD2+ adult acute promyelocytic leukemia and the CD34?CD2? hyergranular and microgranular (M3v) phenotypes, Haematologica, vol.91, pp.311-316, 2006. ,
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens, Blood, vol.117, issue.6, pp.1799-1805, 2011. ,
DOI : 10.1182/blood-2010-04-277434
Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts, Cancer Science, vol.120, issue.1, pp.97-104, 2014. ,
DOI : 10.1182/blood-2012-02-410746
Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients, Leukemia Research, vol.38, issue.2, pp.194-197, 2014. ,
DOI : 10.1016/j.leukres.2013.11.008
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial, British Journal of Haematology, vol.84, issue.3, pp.801-807, 2000. ,
DOI : 10.1056/NEJM199710093371501
The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor ?? gene to a novel transcribed locus, Nature, vol.347, issue.6293, pp.558-61, 1990. ,
DOI : 10.1038/347558a0
Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17, Science, vol.249, issue.4976, pp.1577-80, 1990. ,
DOI : 10.1126/science.2218500
The PML-RARalpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell, pp.675-84, 1991. ,
Molecular analysis of the PML/RARalpha chimeric gene in pediatric acute promyelocytic leukemia, Leukemia, vol.10, issue.8, pp.1296-302, 1996. ,
Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study, Blood, vol.90, pp.1656-1663, 1997. ,
All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship, Blood, vol.76, issue.9, pp.1710-1717, 1990. ,
The nuclear receptor superfamily: The second decade, Cell, vol.83, issue.6, pp.835-844, 1995. ,
DOI : 10.1016/0092-8674(95)90199-X
A decade of molecular biology of retinoic acid receptors., The FASEB Journal, vol.10, issue.9, 1996. ,
DOI : 10.1096/fasebj.10.9.8801176
Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell, pp.373-80, 1997. ,
Isotype-Restricted Corepressor Recruitment: a Constitutively Closed Helix 12 Conformation in Retinoic Acid Receptors ?? and ?? Interferes with Corepressor Recruitment and Prevents Transcriptional Repression, Molecular and Cellular Biology, vol.23, issue.8, 2003. ,
DOI : 10.1128/MCB.23.8.2844-2858.2003
Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science, pp.1354-1361, 1995. ,
The nuclear hormone receptor coactivator SRC-1 is a specific target of p300., Proceedings of the National Academy of Sciences, vol.93, issue.20, pp.10626-10657, 1996. ,
DOI : 10.1073/pnas.93.20.10626
Positive and negative regulation of granulopoiesis by endogenous RARalpha, Blood, vol.97, issue.5, pp.1314-1334, 2001. ,
DOI : 10.1182/blood.V97.5.1314
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell, pp.663-74, 1991. ,
TRIM/RBCC, a novel class of ???single protein RING finger??? E3 ubiquitin ligases, BioEssays, vol.15, issue.11, pp.1147-57, 2005. ,
DOI : 10.4049/jimmunol.170.7.3653
The tripartite motif family identifies cell compartments, The EMBO Journal, vol.20, issue.9, pp.2140-51, 2001. ,
DOI : 10.1093/emboj/20.9.2140
TRIM proteins and cancer, Nature Reviews Cancer, vol.121, issue.11, pp.792-804, 2011. ,
DOI : 10.1172/JCI45213
Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins, Embo J. Feb, vol.11, issue.2, pp.629-671, 1992. ,
Differential Roles of PML Isoforms, Frontiers in Oncology, vol.3, p.125, 2013. ,
DOI : 10.3389/fonc.2013.00125
PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence, Proceedings of the National Academy of Sciences, vol.3, issue.7, pp.14278-83, 2015. ,
DOI : 10.1128/MCB.01064-14
URL : http://www.pnas.org/content/112/46/14278.full.pdf
A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells, Journal of Cell Science, vol.120, issue.18, pp.3219-3246, 2007. ,
DOI : 10.1242/jcs.007492
PML Nuclear Bodies, Cold Spring Harbor Perspectives in Biology, vol.2, issue.5, p.661, 2010. ,
DOI : 10.1101/cshperspect.a000661
URL : https://hal.archives-ouvertes.fr/hal-00102123
Pml Is Critical for Nd10 Formation and Recruits the Pml-Interacting Protein Daxx to This Nuclear Structure When Modified by Sumo-1, The Journal of Cell Biology, vol.8, issue.2, pp.221-255, 1999. ,
DOI : 10.1038/24628
-Induced Pml or Pml/Retinoic Acid Receptor ?? Degradation, The Journal of Experimental Medicine, vol.73, issue.12, pp.1361-71, 2001. ,
DOI : 10.1038/sj.onc.1202366
URL : http://jem.rupress.org/content/jem/193/12/1361.full.pdf
Regulation of p53 activity in nuclear bodies by a specific PML isoform, The EMBO Journal, vol.19, issue.22, pp.6185-95, 2000. ,
DOI : 10.1093/emboj/19.22.6185
The function of PML in p53-dependent apoptosis, Nature Cell Biology, vol.18, issue.10, pp.730-736, 2000. ,
DOI : 10.1093/emboj/18.20.5609
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras, Nature, vol.391, issue.6792, pp.207-217, 2000. ,
DOI : 10.1038/35901
PML Is a Direct p53 Target that Modulates p53 Effector Functions, Molecular Cell, vol.13, issue.4, pp.523-558, 2004. ,
DOI : 10.1016/S1097-2765(04)00062-0
Impairment of p53 acetylation, stability and function by an oncogenic transcription factor, The EMBO Journal, vol.23, issue.5, pp.1144-54, 2004. ,
DOI : 10.1038/sj.emboj.7600109
Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling, Cell Cycle, vol.9, issue.15, pp.3085-99, 2010. ,
DOI : 10.4161/cc.9.15.12521
Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes, Blood. Jul, vol.1594, issue.2, pp.793-802, 1999. ,
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure, Nature Reviews Cancer, vol.112, issue.11, pp.775-83, 2010. ,
DOI : 10.1016/j.bbagrm.2009.07.001
PML???RARA-RXR Oligomers Mediate Retinoid and Rexinoid/cAMP Cross-Talk in Acute Promyelocytic Leukemia Cell Differentiation, The Journal of Experimental Medicine, vol.6, issue.8, 2004. ,
DOI : 10.1073/pnas.180290497
PML- RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell, Feb, vol.1717, issue.2, pp.173-85, 2010. ,
Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia, Embo J, vol.12, issue.3, pp.1161-1168, 1993. ,
Variations on a theme: the alternate translocations in APL, Leukemia, vol.16, issue.10, 2002. ,
DOI : 10.1038/sj.leu.2402720
BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia, Blood, vol.116, issue.20, pp.4274-83, 2010. ,
DOI : 10.1182/blood-2010-01-264432
OBFC2A/RARA: a novel fusion gene in variant acute promyelocytic leukemia, Blood, vol.121, issue.8, pp.1432-1437, 2013. ,
DOI : 10.1182/blood-2012-04-423129
Acute promyelocytic leukemia: results of treatment by daunorubicin, Blood, vol.41, issue.4, pp.489-96, 1973. ,
Retinoic acid treatment ofacute promyelocytic leukemia: In vitro and in vivo observations, Blood, vol.62, p.1211, 1983. ,
Probable in vivo induction of differentiation by retinoic acid of promyelocytes in acute promyelocytic leukaemia, British Journal of Haematology, vol.38, issue.3, p.365, 1984. ,
DOI : 10.1016/S0140-6736(77)91415-5
Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia, Blood, vol.67, p.559, 1986. ,
The role of 13 cis-retinoic acid in the remission induction of a patient with acute promyelocytic leukemia, Cancer, vol.53, issue.2, p.209, 1986. ,
DOI : 10.1073/pnas.68.2.378
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia, Blood, vol.72, issue.2, pp.567-72, 1988. ,
Effect of all trans-retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group, Blood, vol.82, issue.11, pp.3241-3250, 1993. ,
Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia, Leukemia, vol.14, issue.8, pp.1371-1378, 2000. ,
DOI : 10.1038/sj.leu.2401859
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group, Blood, vol.94, issue.4, pp.1192-200, 1999. ,
Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy, Blood, vol.90, p.1014, 1997. ,
All trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia, Blood, 1995. ,
Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid, Blood, vol.57, issue.6, pp.1000-1004, 1981. ,
All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood, pp.1704-1713, 1990. ,
Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia, The Lancet, vol.343, issue.8904, p.1033, 1994. ,
DOI : 10.1016/S0140-6736(94)90151-1
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia, Blood, vol.72, issue.2, pp.567-72, 1988. ,
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation, Nature Medicine, vol.341, issue.12, 2008. ,
DOI : 10.1038/nm.1891
URL : https://hal.archives-ouvertes.fr/inserm-00350912
Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies, The Journal of Experimental Medicine, vol.1333, issue.4, pp.647-53, 2013. ,
DOI : 10.1016/j.ccr.2005.01.005
Activation of a promyelocytic leukemia???tumor protein 53 axis underlies acute promyelocytic leukemia cure, Nature Medicine, vol.70, issue.2, pp.167-74, 2014. ,
DOI : 10.1158/0008-5472.CAN-10-2014
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway, Cancer Res, 1996. ,
Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha ) and oncogenic RARalpha fusion proteins, Proceedings of the National Academy of Sciences, vol.90, issue.1, pp.14807-14819, 1999. ,
DOI : 10.1016/S0092-8674(00)80317-7
Dimerization with Retinoid X Receptors and Phosphorylation Modulate the Retinoic Acid-induced Degradation of Retinoic Acid Receptors ?? and ?? through the Ubiquitin-Proteasome Pathway, Journal of Biological Chemistry, vol.19, issue.43, pp.33280-33288, 2000. ,
DOI : 10.1016/S0092-8674(00)80708-4
Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein, Blood, vol.92, issue.7, pp.2244-51, 1998. ,
Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein, Blood, vol.92, issue.7, pp.2244-51, 1998. ,
Pathways of retinoic acid- or arsenic trioxide-induced PML/RAR?? catabolism, role of oncogene degradation in disease remission, Oncogene, vol.20, issue.49, pp.7257-65, 2001. ,
DOI : 10.1073/pnas.94.8.3978
Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations, Blood, vol.113, issue.8, pp.1741-1749, 2009. ,
DOI : 10.1182/blood-2007-12-130260
Genomewide array-based comparative genomic hybridization analysis of acute promyelocytic leukemia, Genes, Chromosomes and Cancer, vol.97, issue.4, pp.420-425, 2006. ,
DOI : 10.1002/gcc.20309
Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients, Blood, vol.94, issue.10, pp.3315-3339, 1999. ,
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia, Proceedings of the National Academy of Sciences, vol.102, issue.1, pp.7653-7658, 2005. ,
DOI : 10.1182/blood-2002-09-2725
Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells, Blood, vol.91, pp.4300-4310, 1998. ,
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia, The Journal of Experimental Medicine, vol.88, issue.13, pp.2793-2802, 2013. ,
DOI : 10.1073/pnas.96.26.14807
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia, Proceedings of the National Academy of Sciences, vol.39, issue.2 Suppl 1, pp.5328-5363, 2004. ,
DOI : 10.1053/shem.2002.33611
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia, Proceedings of the National Academy of Sciences, vol.10, issue.12, pp.3342-3349, 2009. ,
DOI : 10.1200/JCO.2003.04.036
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4), Blood, vol.120, issue.8, pp.1570-1580, 2012. ,
DOI : 10.1182/blood-2012-02-410746
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia, Blood, vol.107, issue.9, pp.3469-3473, 2006. ,
DOI : 10.1182/blood-2005-10-4006
Phase II study of alltrans retinoic acid (ATRA), arsenic trioxide (ATO), with or without gemtuzumab ozogamicin (GO) for the frontline therapy of patients with acute promyelocytic leukemia (APL), Blood (ASH Annual Meeting Abstracts), vol.116, 2010. ,
Therapy-related MDS and AML in acute promyelocytic leukemia, Blood, vol.100, issue.5, pp.1928-1929, 2002. ,
DOI : 10.1182/blood-2002-03-0962
Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL), Leukemia, vol.16, issue.9 ,
DOI : 10.1038/sj.leu.2402616
Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem, Blood, vol.99, issue.3, pp.822-824, 2002. ,
DOI : 10.1182/blood.V99.3.822
-Retinoic Acid and Anthracycline-Based Chemotherapy, Journal of Clinical Oncology, vol.28, issue.24, pp.3872-3879, 2010. ,
DOI : 10.1200/JCO.2010.29.2268
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia, New England Journal of Medicine, vol.369, issue.2, pp.111-121, 2013. ,
DOI : 10.1056/NEJMoa1300874
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non???High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial, Journal of Clinical Oncology, vol.35, issue.6, pp.605-612, 2017. ,
DOI : 10.1200/JCO.2016.67.1982
Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation, Blood, vol.124, issue.25, 2014. ,
DOI : 10.1182/blood-2014-03-561852
Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1333, issue.3, pp.53-61, 1997. ,
DOI : 10.1016/S0304-419X(97)00025-5
Oxidative stress???induced assembly of PML nuclear bodies controls sumoylation of partner proteins, The Journal of Cell Biology, vol.95, issue.6, pp.931-976, 2014. ,
DOI : 10.1083/jcb.201305148.dv
URL : https://hal.archives-ouvertes.fr/hal-00992287
Arsenic degrades PML or PML???RAR?? through a SUMO-triggered RNF4/ubiquitin-mediated pathway, Nature Cell Biology, vol.112, issue.5, pp.547-55, 2008. ,
DOI : 10.1038/nmeth891
RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation, Nature Cell Biology, vol.112, issue.5, pp.538-584, 2008. ,
DOI : 10.1042/BJ20052030
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells, Blood, vol.89, issue.9, pp.3345-53, 1997. ,
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins, Blood, vol.88, issue.3, pp.1052-61, 1996. ,
Resistance to Therapy in Acute Promyelocytic Leukemia, New England Journal of Medicine, vol.371, issue.12, pp.1170-1172, 2014. ,
DOI : 10.1056/NEJMc1409040
Missense mutations in PML- RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood, pp.1600-1609, 2011. ,
Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia, New England Journal of Medicine, vol.370, issue.19, pp.1864-1870, 2014. ,
DOI : 10.1056/NEJMc1316382
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience, Blood, vol.115, issue.9, pp.1690-1696, 2010. ,
DOI : 10.1182/blood-2009-07-233387
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol, Blood, vol.100, issue.13, pp.4298-302, 2002. ,
DOI : 10.1182/blood-2002-02-0632
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance, Blood, vol.117, issue.18, pp.4716-4741, 2011. ,
DOI : 10.1182/blood-2010-08-302950
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group, Blood, vol.112, issue.8, pp.3130-3134, 2008. ,
DOI : 10.1182/blood-2008-05-159632
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome, Blood, vol.115, issue.25, pp.5137-5183, 2010. ,
DOI : 10.1182/blood-2010-01-266007
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood, pp.1935-1978, 2013. ,
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial, The Lancet Haematology, vol.2, issue.9, pp.357-66, 2015. ,
DOI : 10.1016/S2352-3026(15)00115-5
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin, Blood, vol.111, issue.7, pp.3395-402, 2008. ,
DOI : 10.1182/blood-2007-07-100669
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710, Blood, vol.116, issue.19, pp.3751-3758, 2010. ,
DOI : 10.1182/blood-2010-02-269621
Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry, Leukemia, vol.88, issue.7, pp.1128-1162, 2011. ,
DOI : 10.1111/j.1600-0609.2006.00803.x
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid, Blood, vol.118, issue.5, 2011. ,
DOI : 10.1182/blood-2011-04-346437
Treatment advances have not improved the early death rate in acute promyelocytic leukemia, Haematologica, vol.97, issue.1, pp.133-139, 2012. ,
DOI : 10.3324/haematol.2011.046490
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death, Leukemia Research, vol.37, issue.9, pp.1004-1013, 2013. ,
DOI : 10.1016/j.leukres.2013.05.007
Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study, British Journal of Haematology, vol.88, issue.5, pp.660-666, 2014. ,
DOI : 10.1002/cncr.24440
Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines, Haematologica, vol.92, issue.10, pp.1431-1433, 2007. ,
DOI : 10.3324/haematol.10874
Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: Final results of a multicentric study in the United States, Leukemia Research, vol.38, issue.9, 2014. ,
DOI : 10.1016/j.leukres.2014.06.011
Treatment of elderly patients (???60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols, Leukemia, vol.99, issue.Suppl 1, pp.1085-1090, 2003. ,
DOI : 10.1182/blood.V99.3.822
All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia, Blood, vol.104, issue.12, pp.3490-3493, 2004. ,
DOI : 10.1182/blood-2004-04-1642
Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience, Leukemia, vol.99, issue.2, pp.230-233, 2005. ,
DOI : 10.1182/blood.V99.9.3136
GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors, British Journal of Haematology, vol.47, issue.5, pp.564-572, 2011. ,
DOI : 10.1080/10428190600807178
Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia, Cancer Science, vol.19, issue.11, pp.1974-1978, 2012. ,
DOI : 10.1038/sj.leu.2403807
Management of elderly patients with acute promyelocytic leukemia: progress and problems, Annals of Hematology, vol.117, issue.9, pp.1181-1188, 2013. ,
DOI : 10.1159/000097880
Acute promyelocytic leukemia in patients aged 70 years and over???A single center experience of unselected patients, Leukemia & Lymphoma, vol.92, issue.8, pp.1654-1658, 2007. ,
DOI : 10.1002/cncr.21006
Acute promyelocytic leukemia in very elderly patients: still a clinical challenge, Leukemia & Lymphoma, vol.10, issue.1, pp.119-121, 2009. ,
DOI : 10.1182/blood-2005-10-4006
Treatment of elderly adults with acute promyelocytic leukemia: put the pedal to metal, Leukemia & Lymphoma, vol.50, issue.1, pp.12-13, 2009. ,
DOI : 10.1182/blood.V99.9.3136
Acute promyelocytic leukemia in patients aged >70??years: the cure beyond the age, Annals of Hematology, vol.369, issue.2, 2015. ,
DOI : 10.1056/NEJMoa1300874
Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation, Haematologica, vol.95, issue.5, pp.853-854, 2010. ,
DOI : 10.3324/haematol.2009.017962
Presenting white blood cell counts and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: results of the randomized MRC trial, Blood, vol.93, pp.4131-4143, 1999. ,
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial, Leukemia, vol.94, issue.4, pp.843-851, 2013. ,
DOI : 10.1038/sj.leu.2404501
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG, Leukemia, vol.95, issue.12, pp.2248-2258, 2009. ,
DOI : 10.1182/blood-2008-07-168617
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group, Annals of Hematology, vol.51, issue.17, pp.41-52, 2013. ,
DOI : 10.1002/gcc.21961
The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia, Annals of Internal Medicine, vol.117, issue.4, p.292, 1992. ,
DOI : 10.7326/0003-4819-117-4-292
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors, Blood, vol.113, issue.4, p.775, 2009. ,
DOI : 10.1182/blood-2008-07-168617
Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid, Blood, vol.84, pp.3843-3849, 1994. ,
Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome, Blood, vol.95, pp.90-95, 2000. ,
Leukocytosis and the Retinoic Acid Syndrome in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide, Journal of Clinical Oncology, vol.18, issue.13, p.2620, 2000. ,
DOI : 10.1200/JCO.2000.18.13.2620
Alltrans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer, pp.2946-52, 1994. ,
AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study, Blood, vol.88, issue.4, pp.1390-1398, 1996. ,
All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study, Annals of Internal Medicine, vol.120, issue.4, pp.278-86, 1994. ,
DOI : 10.7326/0003-4819-120-4-199402150-00004
Diffuse Alveolar Hemorrhage with Underlying Pulmonary Capillaritis in the Retinoic Acid Syndrome, American Journal of Respiratory and Critical Care Medicine, vol.262, issue.4, pp.1302-1307, 1998. ,
DOI : 10.1002/jcb.240590802
Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome, Blood, vol.114, issue.27, pp.5512-5533, 2009. ,
DOI : 10.1182/blood-2009-02-204834
Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group, Blood, vol.92, issue.8, pp.2712-2720, 1998. ,
Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial, Leukemia, vol.6, issue.2, pp.339-381, 2003. ,
DOI : 10.2307/2344317
Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group, Leukemia, vol.9, pp.774-778, 1995. ,
High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia, Leukemia Research, vol.34, issue.4, pp.545-552, 2010. ,
DOI : 10.1016/j.leukres.2009.09.017
URL : https://hal.archives-ouvertes.fr/pasteur-01375286
Acute promyelocytic leukemia???clinical management of 15 patients, American Journal of Hematology, vol.52, issue.4, pp.347-359, 1980. ,
DOI : 10.1016/S0025-7125(16)31285-8
Acute Promyelocytc Leukemia, Acta Medica Scandinavica, vol.58, issue.3, pp.189-194, 1957. ,
DOI : 10.1001/jama.1955.02950310038009
Acute promyelocytic leukemia, The American Journal of Medicine, vol.80, issue.5, pp.789-97, 1986. ,
DOI : 10.1016/0002-9343(86)90617-0
Acute promyelocytic leukemia in 57 previously untreated patients. Cancer, pp.18-25, 1985. ,
DOI : 10.1002/1097-0142(19850101)55:1<18::aid-cncr2820550104>3.0.co;2-b
URL : http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19850101)55:1<18::AID-CNCR2820550104>3.0.CO;2-B/pdf
Acute promyelocytic leukemia: clinical aspects and results of treatment in 62 patients, Haematologica, vol.72, issue.2, pp.151-156, 1987. ,
Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients, Blood, vol.71, issue.3, pp.690-696, 1988. ,
The coagulopathy of acute promyelocytic leukaemia revisited, Best Practice & Research Clinical Haematology, vol.22, issue.1, pp.153-163, 2009. ,
DOI : 10.1016/j.beha.2008.12.007
The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia, British Journal of Haematology, vol.72, issue.1, pp.24-36, 2012. ,
DOI : 10.1111/j.1600-0609.2004.00237.x
Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment, Leukemia, vol.7, issue.1, pp.2-9, 1993. ,
Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Keio Hematology-Oncology Cooperative Study Group (KHOCS) Thromb Haemost, pp.641-646, 1997. ,
Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia, Journal of Thrombosis and Haemostasis, vol.95, issue.8, 2004. ,
DOI : 10.7326/0003-4819-117-4-292
A new procoagulant in acute leukemia, Blood, vol.71, pp.870-875, 1988. ,
Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid, Blood, vol.86, issue.3, pp.1072-81, 1995. ,
Procoagulant activity of the VX2 carcinoma: tissue factor activity is expressed by tumor cells, Clin Res, vol.37, p.466, 1989. ,
One-Stage Method for Assay of Tissue Factor Activity of Leukemic Cell with Special Reference to Disseminated Intravascular Coagulation, American Journal of Clinical Pathology, vol.93, issue.5, pp.679-84, 1990. ,
DOI : 10.1093/ajcp/93.5.679
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia, Best Practice & Research Clinical Haematology, vol.16, issue.3, pp.463-82, 2003. ,
DOI : 10.1016/S1521-6926(03)00059-8
Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity., Proceedings of the National Academy of Sciences, vol.83, issue.10, pp.3460-3464, 1986. ,
DOI : 10.1073/pnas.83.10.3460
Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1., Proceedings of the National Academy of Sciences, vol.83, issue.12, pp.4533-4540, 1986. ,
DOI : 10.1073/pnas.83.12.4533
Interleukin 1 stimulates endothelial cell tissue factor production and expression by a prostaglandin-independent mechanism, Thromb Haemost, vol.56, pp.256-265, 1986. ,
Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 ,
Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin, International Journal of Hematology, vol.8, issue.126, pp.27-37 ,
DOI : 10.7326/0003-4819-120-4-199402150-00004
Cytokine regulation of endothelial cell function., The FASEB Journal, vol.6, issue.8, pp.2591-2599, 1992. ,
DOI : 10.1096/fasebj.6.8.1592209
Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome, Blood, vol.114, issue.27, pp.5512-5521, 2009. ,
DOI : 10.1182/blood-2009-02-204834
Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial, Journal of Thrombosis and Haemostasis, vol.61, issue.1, pp.31-41, 2007. ,
DOI : 10.1046/j.1523-1755.2002.00160.x
Successful Control of Disseminated Intravascular Coagulation by Recombinant Thrombomodulin during Arsenic Trioxide Treatment in Relapsed Patient with Acute Promyelocytic Leukemia, Case Reports in Hematology, vol.19, issue.18, p.908196, 2012. ,
DOI : 10.1160/TH10-12-0802
Clinical Features and Treatment Outcomes of Six Patients with Disseminated Intravascular Coagulation Resulting from Acute Promyelocytic Leukemia and Treated with Recombinant Human Soluble Thrombomodulin at a Single Institution, Internal Medicine, vol.52, issue.1, pp.55-62, 2013. ,
DOI : 10.2169/internalmedicine.52.7978
Recombinant human soluble thrombomodulin counteracts capillary leakage associated with engraftment syndrome, Bone Marrow Transplantation, vol.101, issue.4, pp.616-624, 2011. ,
DOI : 10.1172/JCI200522782
Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin, Bone Marrow Transplantation, vol.82, issue.4, pp.783-788, 2010. ,
DOI : 10.1172/JCI200522782
Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents, Leukemia, vol.13, issue.7, pp.1062-70, 1999. ,
DOI : 10.1038/sj.leu.2401448
Apoptosis is associated with increased cell surface tissue factor procoagulant activity, Lab Invest, vol.75, pp.281-289, 1996. ,
Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus., Proceedings of the National Academy of Sciences, vol.93, issue.4, pp.1624-1629, 1996. ,
DOI : 10.1073/pnas.93.4.1624
Thrombin generation by apoptotic vascular smooth muscle cells, Blood, vol.89, pp.4378-4384, 1997. ,
Pathogenesis of increased risk of thrombosis in cancer, Semin Thromb Hemost, vol.29, pp.283-290, 2003. ,
Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia, Journal of Thrombosis and Haemostasis, vol.24, issue.4, pp.773-82, 2010. ,
DOI : 10.1002/cyto.a.20345
Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid, Blood, vol.97, issue.12, pp.3919-3924, 2001. ,
DOI : 10.1182/blood.V97.12.3919
Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia, Leukemia & Lymphoma, vol.10, issue.1, pp.81-89, 2006. ,
DOI : 10.1038/sj.neo.7900123
Inhibitory effect of retinoids on the generation of procoagulant activity by blood mononuclear phagocytes, Thromb Haemost, vol.66, issue.6, pp.662-667, 1991. ,
Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy, Journal of Thrombosis and Haemostasis, vol.5, issue.1, 2011. ,
DOI : 10.1111/j.1538-7836.2007.02369.x
Role of Microparticles in the Hemostatic Dysfunction in Acute Promyelocytic Leukemia, Seminars in Thrombosis and Hemostasis, vol.36, issue.08, pp.36-917, 2010. ,
DOI : 10.1055/s-0030-1267045
The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination, British Journal of Haematology, vol.61, issue.4, pp.511-517, 1989. ,
DOI : 10.1021/bi00628a023
The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia, Blood, vol.77, pp.1949-1957, 1991. ,
In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy, Leukemia, vol.9, pp.19-24, 1995. ,
Annexin II and Bleeding in Acute Promyelocytic Leukemia, New England Journal of Medicine, vol.340, issue.13, pp.994-1004, 1999. ,
DOI : 10.1056/NEJM199904013401303
Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages, Blood, vol.103, issue.1, pp.317-324, 2004. ,
DOI : 10.1182/blood-2003-04-1304
URL : http://www.bloodjournal.org/content/bloodjournal/103/1/317.full.pdf
Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin, Journal of Thrombosis and Haemostasis, vol.126, issue.2, pp.306-312, 2004. ,
DOI : 10.1161/01.CIR.84.6.2568
Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia, Blood, vol.120, issue.1, pp.207-213, 2012. ,
DOI : 10.1182/blood-2011-04-347187
Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors, Thrombosis Research, vol.6, issue.4, pp.315-329, 1975. ,
DOI : 10.1016/0049-3848(75)90081-X
Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with all-trans-retinoic acid, British Journal of Haematology, vol.92, issue.3, pp.733-739, 1996. ,
DOI : 10.1046/j.1365-2141.1996.401939.x
The Role of Von Willebrand Factor in the Hemostatic Defect of Acute Promyelocytic Leukemia, Leukemia & Lymphoma, vol.65, issue.5-6, pp.491-499, 1998. ,
DOI : 10.1073/pnas.89.17.7880
Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator, Thrombosis Research, vol.106, issue.1, pp.63-70, 2002. ,
DOI : 10.1016/S0049-3848(02)00075-0
All-trans retinoic acid-induced downregulation of annexin II expression in myeloid leukaemia cell lines is not confined to acute promyelocytic leukaemia, British Journal of Haematology, vol.41, issue.2, pp.258-264, 2005. ,
DOI : 10.1016/S0049-3848(02)00075-0
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group, Blood, vol.116, issue.17, pp.1163171-1163180, 2010. ,
DOI : 10.1182/blood-2010-03-276196
Updates on the treatment of acute promyelocytic leukemia, Clin Adv Hematol Oncol, vol.8, issue.2, pp.89-90, 2010. ,
Early deaths and antihemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients, Blood, issue.11, pp.75-2112, 1990. ,
Pathogenesis of Thrombosis in Essential Thrombocythemia and Polycythemia Vera: The Role of Neutrophils, Seminars in Hematology, vol.42, issue.4, pp.239-286, 2005. ,
DOI : 10.1053/j.seminhematol.2005.05.023
The management of bleeding and thrombosis in acute leukemia and chronic myeloproliferative disorders, Leukemia, pp.263-82, 2001. ,
Pathogenesis of Thrombosis in Patients with Malignancy, International Journal of Hematology, vol.5, issue.suppl 3, pp.137-181, 2001. ,
DOI : 10.1111/j.1365-2141.1992.tb02978.x
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group, Blood, vol.103, issue.4, pp.1237-1280, 2004. ,
DOI : 10.1182/blood-2003-07-2462
Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage, Leukemia, 1994. ,
The impact of all-transretinoic acid on the coagulopathy of acute promyelocytic leukemia, Blood, vol.91, pp.3093-102, 1998. ,
Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine., Journal of Clinical Oncology, vol.15, issue.2, pp.483-90, 1997. ,
DOI : 10.1200/JCO.1997.15.2.483
-Retinoic Acid in Acute Promyelocytic Leukemia, New England Journal of Medicine, vol.337, issue.15, pp.1021-1029, 1997. ,
DOI : 10.1056/NEJM199710093371501
A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group, Blood, vol.94, issue.9, pp.3015-3036, 1999. ,
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia, Leukemia, vol.14, issue.8, pp.1362-70, 2000. ,
DOI : 10.1038/sj.leu.2401843
Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG), Cancer Chemotherapy and Pharmacology, vol.48, issue.0, pp.65-71, 2001. ,
DOI : 10.1007/s002800100308
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia, Leukemia, vol.15, issue.6, pp.978-83, 2005. ,
DOI : 10.1038/sj.leu.2402205
Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome, European Journal of Haematology, vol.77, issue.3, pp.213-222, 2007. ,
DOI : 10.1111/j.1538-7836.2004.00787.x
Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMA, European Journal of Haematology, vol.70, issue.suppl 178, pp.257-60, 1990. ,
DOI : 10.1056/NEJM198107163050305
The GIMEMA protocol LAP (0389) for the treatment of acute promyelocytic leukemia (APL) Preliminary results, Proceedings of the 24th Congress of the International Society of Hematology (Abstract), p.842, 1992. ,
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry, Blood, vol.113, issue.18, pp.4179-4187, 2009. ,
DOI : 10.1182/blood-2008-07-172007
Open issues on bleeding and thrombosis in acute promyelocytic leukemia, Thrombosis Research, vol.125, issue.2, pp.51-54, 2010. ,
DOI : 10.1016/S0049-3848(10)70013-X
International Classification of Diseases for Oncology (ICD-O), World Health, 2000. ,
Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti- PML). Blood, pp.4046-53, 1997. ,
Caracter??sticas hematol??gicas e perfil de express??o de ant??genos miel??ides de pacientes com leucemia promieloc??tica aguda: an??lise de fatores progn??sticos para o desenvolvimento da s??ndrome do ??cido retin??ico, Revista da Associa????o M??dica Brasileira, vol.50, issue.3, pp.286-92, 1992. ,
DOI : 10.1590/S0104-42302004000300036
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results, Blood, vol.111, issue.3, pp.1078-84, 2008. ,
DOI : 10.1182/blood-2007-07-099978
Management of APL in Developing Countries: Epidemiology, Challenges and Opportunities for International Collaboration, Hematology, vol.2006, issue.1, pp.162-168, 2006. ,
DOI : 10.1182/asheducation-2006.1.162
Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients, Leukemia, vol.166, issue.12, pp.2422-2426, 2014. ,
DOI : 10.1111/bjh.12931